Aeglea BioTherapeutics
demonstrates durable clinical response at week analysis achievement of in one or more of three | Aeglea BioTherapeutics
Company
Deck Type
Sector
Industry
Deck date
May 2020
Slide
11 of 13
Related slides by other companies
Chimerix
Investor Presentation
May 2023
clinically meaningful and durable responses | Chimerix
Genelux
Investor Presentation
October 2023
clinically meaningful responses in heavily patients rescore a | Genelux
Nuvalent
Investor Presentation
February 2024
activity induced intracranial responses in patients with refractory alk phase refractory complete response alk fusion alk fusion no known resistance mutations lines of therapy including and chemotherapy complete resolution of parietal parenchymal brain metastases after weeks treatment continues at months ongoing mutation weeks resistance alk fusion partial response ongoing confirmed lines of therapy consisting treatment continues at after weeks of and months weeks confirmed courtesy of and hospital vall barcelona courtesy of university united states data as of august central nervous system complete response non small source lin cell lung cancer partial response once daily tyrosine kinase inhibitor | Nuvalent
Alkermes
Results
June 2021
artistry responses in renal cell carcinoma patients | Alkermes
Other recent decks by Aeglea BioTherapeutics
See all presentations (14 decks)
Investor Presentation
October 2023
Investor Presentation
October 2023
Investor Presentation
September 2023
Investor Presentation
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io